Komori
Share Issuance and Disposal4893Noile-Immune Biotech Inc.Pharmaceuticals

Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Adjustment Provisions

In October 2026, 14,100 Series 14 Stock Acquisition Rights were exercised and 1,410,000 new shares were issued. The number of unexercised Stock Acquisition Rights at month-end was 85,900.

Worth reading
55In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1410000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise status of warrants with exercise price adjustment clauses (monthly report)

発行・処分する株式数

1,410,000 new shares; 0 treasury shares transferred

発行済株式総数

3.25% (1,410,000 shares issued across all series combined / 43,399,118 listed shares as of the payment date for the issuance)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
The exercise prices in October 2026 were ¥99, ¥95, ¥94, ¥88, ¥85, ¥84, ¥83 and ¥82. Details and the floor price under the adjustment provision: Not disclosed
Number of Stock Acquisition Rights
Total issued: 100,000 units; unexercised as of 5 October 2026: 100,000 units; exercised during the target month: 14,100 units; unexercised at the end of the target month: 85,900 units
Procedures under the Corporate Code of Conduct
Report on compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange Securities Listing Regulations and the Japan Securities Dealers Association Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing
Timing 5 October 2026 / Type Series 14 Stock Acquisition Rights (with an exercise price adjustment provision) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise status of warrants with exercise price adjustment clauses (monthly report)
Number of shares to be issued or disposed of1,410,000 new shares; 0 treasury shares transferred
Dilution Rate3.25% (1,410,000 shares issued across all series combined / 43,399,118 listed shares as of the payment date for the issuance)
Total number of issued shares43,399,118 shares (as of the end of the month preceding the target month, including 125 treasury shares) → Not disclosed
Exercise priceThe exercise prices in October 2026 were ¥99, ¥95, ¥94, ¥88, ¥85, ¥84, ¥83 and ¥82. Details and the floor price under the adjustment provision: Not disclosed
Number of Stock Acquisition RightsTotal issued: 100,000 units; unexercised as of 5 October 2026: 100,000 units; exercised during the target month: 14,100 units; unexercised at the end of the target month: 85,900 units
Procedures under the Corporate Code of ConductReport on compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange Securities Listing Regulations and the Japan Securities Dealers Association Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financingTiming 5 October 2026 / Type Series 14 Stock Acquisition Rights (with an exercise price adjustment provision) / Amount Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the exercise status for October 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Adjustment Provisions | Noile-Immune Biotech Inc. (4893) timely disclosure | Komori